1 |
Gutmann DH, Parada LF, Silva AJ, Ratner N. Neurofibromatosis type 1: modeling CNS dysfunction. J Neurosci 2012;32:14087-93.
DOI
|
2 |
Nix JS, Blakeley J, Rodriguez FJ. An update on the central nervous system manifestations of neurofibromatosis type 1. Acta Neuropathol 2020;139:625-41.
DOI
|
3 |
Huson SM. The neurofibromatoses: classification, clinical features and genetic counselling. Monogr Hum Genet 2008;16:1-20.
|
4 |
Hoefnagel D, Andrew ED, Mireault NG, Berndt WO. Hereditary choreoathetosis, self-mutilation and hyperuricemia in young males. N Engl J Med 1965;273:130-5.
DOI
|
5 |
Lesch M, Nyhan WL. A familial disorder of uric acid metabolism and central nervous system function. Am J Med 1964;36:561-70.
DOI
|
6 |
Torres RJ, Puig JG. Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. Orphanet J Rare Dis 2007;2:48.
|
7 |
Anderson LT, Ernst M, Davis SV. Cognitive abilities of patients with Lesch-Nyhan disease. J Autism Dev Disord 1992;22:189-203.
DOI
|
8 |
Anderson LT, Ernst M. Self-injury in Lesch-Nyhan disease. J Autism Dev Disord 1994;24:67-81.
DOI
|
9 |
Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol 2014;13:834-43.
DOI
|
10 |
Vogel AC, Gutmann DH, Morris SM. Neurodevelopmental disorders in children with neurofibromatosis type 1. Dev Med Child Neurol 2017;59:1112-6.
DOI
|
11 |
Jinnah HA. HPRT1 disorders. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, et al., eds. GeneReviews®. Seattle (WA): University of Washington, 2020.
|
12 |
Visser JE, Bar PR, Jinnah HA. Lesch-Nyhan disease and the basal ganglia. Brain Res Rev 2000;32:449-75.
DOI
|
13 |
Jinnah HA, Visser JE, Harris JC, Verdu A, Larovere L, Ceballos-Picot I, et al.; Lesch-Nyhan Disease International Study Group. Delineation of the motor disorder of Lesch-Nyhan disease. Brain 2006;129(Pt 5):1201-17.
DOI
|
14 |
Jathar P, Panse AM, Jathar M, Gawali PN. Lesch-Nyhan syndrome: disorder of self-mutilating behavior. Int J Clin Pediatr Dent 2016;9:139-42.
DOI
|
15 |
Bell S, Kolobova I, Crapper L, Ernst C. Lesch-Nyhan syndrome: models, theories, and therapies. Mol Syndromol 2016;7:302-11.
DOI
|
16 |
Fu R, Ceballos-Picot I, Torres RJ, Larovere LE, Yamada Y, Nguyen KV, et al.; Lesch-Nyhan Disease International Study Group. Genotype-phenotype correlations in neurogenetics: Lesch-Nyhan disease as a model disorder. Brain 2014;137(Pt 5):1282-303.
DOI
|
17 |
Pride NA, North KN. The cognitive profile of NF1 children: therapeutic implications. In: Upadhyaya M, Cooper D, eds. Neurofibromatosis type 1. Berlin: Springer, 2012;55-69.
|
18 |
Lehtonen A, Howie E, Trump D, Huson SM. Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence. Dev Med Child Neurol 2013;55:111-25.
DOI
|
19 |
Shofty B, Constantini S, Ben-Shachar S. Advances in molecular diagnosis of neurofibromatosis type 1. Semin Pediatr Neurol 2015;22:234-9.
DOI
|